- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05031195
Prognostic Impact of NLR, PLR, and MPV in Patients Undergoing AAA Open Repair
Preoperative Neutrophil to Lymphocyte Ratio, Platelet to Lymphocyte Ratio, and Mean Platelet Volume as Predictors of 1 Year Mortality in Patients Undergoing an Open Repair of Abdominal Aortic Aneurysms: a Retrospective Study
Abdominal aortic aneurysm (AAA) is a multifactorial degenerative disorder, which if untreated might lead to catastrophic complications. The treatment for AAA includes open and endovascular repair, both of which carry a significant degree of risk. Thus, researchers have performed several studies addressing simple and readily available risk stratification markers, such as complete blood count in patients undergoing open AAA repair.
The neutrophil to lymphocyte ratio (NLR) has been frequently used as a marker of systemic inflammatory response, which reflects neutrophilia and lymphopenia. The primary pathophysiology of AAA involves chronic inflammation in the aortic wall and atherosclerosis, accompanied with thrombosis. NLR was proposed as a fair indicator for poor prognosis in patients with AAA. The mean platelet volume (MPV) is the marker of platelet activation and an indicator of the activation of thrombus formation. Moreover, it is reportedly associated with the prognosis of patients with cardiovascular diseases. Moreover, the platelet to lymphocyte ratio (PLR) suggests thrombosis and inflammation and indicates a high risk of cardiovascular events in various groups of patients. The PLR is associated with poor prognosis following AAA repair. Despite accumulating evidence for the prognostic value of white blood cell counts in abdominal aortic aneurysm, few studies have investigated the value of these parameters, including NLR, MPV, and PLR, in patients undergoing AAA open repair.
The investigators aimed to investigate if preoperative neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), or mean platelet volume (MPV) could be used to predict 1-year mortality in patients undergoing open abdominal aortic aneurysm (AAA) repair.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Gangnam Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients who underwent open repair of abdominal aortic aneurysm.
Exclusion Criteria:
- patients with previous aortic repair within 6 months.
- mycotic aneurysm.
- iliac artery aneurysm.
- aorta occlusive disease.
- incomplete data.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
1st tertile
|
Patients will be divided into 3 groups according to the preoperative NLR value.
|
|
2nd tertile
|
Patients will be divided into 3 groups according to the preoperative NLR value.
|
|
3rd tertile
|
Patients will be divided into 3 groups according to the preoperative NLR value.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The incidence of postoperative 1-yr mortality
Time Frame: 1-yr after operation
|
The incidence of postoperative 1-yr mortality in patients undergoing open repair of abdominal aortic aneurysm.
|
1-yr after operation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3-2020-0479
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abdominal Aortic Aneurysm
-
Karolinska University HospitalKarolinska Institutet; Swedish Heart Lung FoundationActive, not recruitingAortic Aneurysm | Aortic Aneurysm Abdominal | Abdominal AneurysmSweden
-
Assistance Publique - Hôpitaux de ParisUnknownSmall Abdominal Aortic Aneurysm | Abdominal Aortic Aneurysm,France
-
EndologixActive, not recruiting1 Paravisceral Abdominal Aortic Aneurysm | 2 Juxtarenal Abdominal Aortic Aneurysm | 3 Pararenal Abdominal Aortic Aneurysm | 4 Complex Abdominal Aortic AneurysmsUnited States
-
Karolinska University HospitalEnrolling by invitationAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm, Ruptured | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without RuptureSweden
-
University of TwenteNot yet recruitingAbdominal Aortic Aneurysm | Endovascular Abdominal Aortic Aneurysm Repair | Fenestrated Endovascular Aortic RepairNetherlands
-
Angiolutions GmbHRecruitingAneurysm, Abdominal AorticUzbekistan
-
Rijnstate HospitalCompletedAAA - Abdominal Aortic AneurysmNetherlands
-
University of PennsylvaniaRecruitingAbdominal Aortic AneurysmUnited States
-
American Heart of PolandRecruitingAbdominal Aortic AneurysmItaly, Poland
-
Washington University School of MedicineRecruitingAbdominal Aortic AneurysmUnited States
Clinical Trials on 1st tertile, 2nd tertile, 3rd tertile
-
University of MichiganNational Institute of Mental Health (NIMH)CompletedSuicide | Self HarmUnited States
-
Children's Hospital of PhiladelphiaRegeneron Pharmaceuticals; Genzyme, a Sanofi CompanyCompletedEosinophilic EsophagitisUnited States
-
Hasan Kalyoncu UniversityCompleted
-
Pediatric Clinical Research PlatformGeneva Emergency Medical Services, Geneva, Switzerland; Lausanne Emergency... and other collaboratorsCompletedReducing Prehospital Medication Errors & Time to Drug Delivery by EMS During Simulated Pediatric CPREmergency Medical Services | Pediatrics | Resuscitation | Cardiopulmonary Arrest | Medication ErrorsSwitzerland
-
Sun Yat-sen UniversityUnknownNecrosis | Glomerulonephritis, IGA | Steroid Nephropathy | Peripapillary CrescentChina
-
Nutricia ResearchCompletedGlycemic ResponseCanada
-
Taipei Medical UniversityRecruitingSedentary Lifestyle | Social Media | Wearable Technology | Health Behavior Change | ChatbotTaiwan
-
University of ArizonaAmgenCompletedSkin Cancer | Squamous Cell Carcinoma | Keratoacanthoma | Cutaneous Tumor | Skin Cancer, Squamous Cell | Lesion SkinUnited States
-
A.O. Ospedale Papa Giovanni XXIIIRegional Hospital of Bolzano; Azienda Ospedaliera San Gerardo di MonzaCompleted